BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/13/2024 3:22:39 AM | Browse: 383 | Download: 848
 |
Received |
|
2024-05-05 09:24 |
|
Peer-Review Started |
|
2024-05-05 09:24 |
|
First Decision by Editorial Office Director |
|
2024-09-26 10:10 |
|
Return for Revision |
|
2024-09-26 10:10 |
|
Revised |
|
2024-10-08 07:34 |
|
Publication Fee Transferred |
|
2024-11-17 22:09 |
|
Second Decision by Editor |
|
2024-11-04 00:25 |
|
Second Decision by Editor-in-Chief |
|
2024-11-06 06:53 |
|
Final Decision by Editorial Office Director |
|
2024-11-12 08:21 |
|
Articles in Press |
|
2024-11-12 08:21 |
 |
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-25 04:48 |
|
Publish the Manuscript Online |
|
2024-12-13 03:22 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34<sup>+</sup> cell therapy: A clinical trial
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Takayasu Ohtake, Tsutomu Sato, Toshitaka Tsukiyama, Suguru Muraoka, Ayaka Mitomo, Haruka Maruyama, Mizuki Yamano, Yasuhiro Mochida, Kunihiro Ishioka, Machiko Oka, Hidekazu Moriya, Sumi Hidaka, Haruchika Masuda, Takayuki Asahara and Shuzo Kobayashi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Takayasu Ohtake, MD, PhD, Regenerative Medicine, The Center for Cell Therapy & Regenerative Medicine, Shonan Kamakura General Hospital, 1370-1 Okamoto, Kamakura 247-8533, Kanagawa, Japan. ohtake@shonankamakura.or.jp |
| Key Words |
CD34+ cell; Chronic kidney disease; Clinical trial; Granulocyte colony-stimulating factor; Regenerative therapy |
| Core Tip |
Chronic kidney disease (CKD) progresses to end-stage renal disease, and it is often very difficult to retard its progression. Therefore, new and effective therapies for CKD are urgently needed. We administered granulocyte colony-stimulating factor-mobilized autologous CD34 positive cells directly into renal arteries. The progressive decline in the estimated glomerular filtration rate improved after 1st cell therapy in three of four patients and was almost preserved after 2nd cell therapy. Although this was an exploratory small clinical trial, the results provide new insights in the field of regenerative medicine for progressive CKD. |
| Publish Date |
2024-12-13 03:22 |
| Citation |
Ohtake T, Sato T, Tsukiyama T, Muraoka S, Mitomo A, Maruyama H, Yamano M, Mochida Y, Ishioka K, Oka M, Moriya H, Hidaka S, Masuda H, Asahara T, Kobayashi S. Preliminary evidence of renal function improvement in chronic progressive kidney disease using autologous CD34+ cell therapy: A clinical trial. World J Stem Cells 2024; 16(12): 1012-1021
|
| URL |
https://www.wjgnet.com/1948-0210/full/v16/i12/1012.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v16.i12.1012 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
